Soligenix (SNGX) Net Equity Issued and Repurchased (2011 - 2018)
Soligenix's (SNGX) quarterly Net Equity Issued and Repurchased came in at $8.6 million in Q3 2018, up 1904.93% YoY from $428870.0 in Q3 2017, and up 46128.74% on a QoQ basis from $18600.0 in Q2 2018.
Soligenix (SNGX) Net Equity Issued and Repurchased (2011 - 2018) Analysis & Trends
Soligenix (SNGX) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $8.6 million in Q3 2018.
- Quarterly Net Equity Issued and Repurchased rose 1904.93% year-over-year to $8.6 million in Q3 2018, while the trailing twelve-month figure through Sep 2023 was $8.6 million (changed N/A YoY) and the FY2016 annual result came in at $3.0 million, down 21.86% from the prior year.
- Net Equity Issued and Repurchased grew to $8.6 million in Q3 2018, from $18600.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $8.6 million in Q3 2018 to a low of $18600.0 in Q2 2018.
- A 5-year average of $1.3 million and a median of $337697.5 in 2015 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2017 — Net Equity Issued and Repurchased plunged 78.95% — and 2018, when it surged 1904.93%.
- Tracing SNGX's Net Equity Issued and Repurchased over 5 years: stood at $156000.0 in 2014, then soared by 1325.74% to $2.2 million in 2015, then retreated by 8.4% to $2.0 million in 2016, then sank by 78.95% to $428870.0 in 2017, then surged by 1904.93% to $8.6 million in 2018.
- The last three Net Equity Issued and Repurchased figures came in at $8.6 million (Q3 2018), $18600.0 (Q2 2018), and $19800.0 (Q1 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 8.60 Mn |
| Sep 30, 2018 | 8.60 Mn |
| Jun 30, 2018 | 18,600.00 |
| Jun 30, 2018 | 18,600.00 |
| Mar 31, 2018 | 19,800.00 |
| Mar 31, 2018 | 19,800.00 |
| Sep 30, 2017 | 428,870.00 |
| Sep 30, 2017 | 428,870.00 |
| Sep 30, 2016 | 2.04 Mn |
| Sep 30, 2016 | 2.04 Mn |
| Dec 31, 2015 | 2.22 Mn |
| Dec 31, 2015 | 2.22 Mn |
| Sep 30, 2015 | 500,000.00 |
| Sep 30, 2015 | 500,000.00 |
| Jun 30, 2015 | 868,500.00 |
| Jun 30, 2015 | 868,500.00 |
| Mar 31, 2015 | 246,525.00 |
| Mar 31, 2015 | 246,525.00 |
| Sep 30, 2014 | 156,000.00 |
| Sep 30, 2014 | 156,000.00 |